Evolent Health, Inc. provided earnings guidance for the fiscal year 2023. For the period, the company expects revenue growth to exceed 25% before any impact from NIA, equating to organic growth of 20%+ and the contribution of seven months of incremental revenue from the IPG acquisition, completed in August.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23 USD | +4.36% | +7.13% | -30.37% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.37% | 2.64B | |
-5.63% | 29.37B | |
+27.86% | 8.52B | |
+26.15% | 4.2B | |
-8.96% | 1.61B | |
-18.87% | 1.4B | |
-34.19% | 1.13B | |
+5.14% | 940M | |
-41.37% | 818M | |
-21.64% | 700M |
- Stock Market
- Equities
- EVH Stock
- News Evolent Health, Inc.
- Evolent Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023